Ocumension Therapeutics (HKG:1477)

Hong Kong · Delayed Price · Currency is HKD

4.880

+0.130 (2.74%)

Jun 18, 2026, 11:57 AM HKT

-52.71% (1Y)

Market Cap	3.87B -33.7%
Revenue (ttm)	895.09M +92.7%
Net Income	-176.74M
EPS	-0.22
Shares Out	815.38M
PE Ratio	n/a
Forward PE	102.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,000
Open	4.760
Previous Close	4.750
Day's Range	4.740 - 4.920
52-Week Range	4.740 - 12.230
Beta	0.39
Analysts	Buy
Price Target	9.66 (+97.95%)
Earnings Date	Mar 26, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation,... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 552

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1477

Full Company Profile

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 1477 stock is "Buy." The 12-month stock price target is $9.66, which is an increase of 97.95% from the latest price.

Price Target

$9.66

(97.95% upside)

Analyst Consensus: Buy

Stock Forecasts